SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTXs rally is fueling unconfirmed speculation about a Big Pharma partnership or buyout, particularly involving Novo, alongside theories of call-driven buying and short covering. Traders also cite the VK2735 obesity-drug program and ObesityWeek presentations, while skeptics argue the move is rumor-driven and may fade without a confirmed deal or new clinical results.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs departure as CEO has fueled uncertainty over Nvidias leadership succession, alongside scrutiny of whether restricted chips reached China through intermediaries. Traders are split between buying the dip and expecting a rebound under new leadership, and warning that investigations and tighter export controls could weigh on the stock.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

A Q3 beat and raised outlook, driven by strong Wegovy pill demand, have fueled renewed optimism about Novo Nordisks recovery. Traders welcome the momentum but debate whether it can offset diabetes weakness, pricing pressure and competition from Lilly.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Shares are under pressure after a quarterly revenue miss, with traders focused on cash runway and criticizing managements lack of guidance. The community is split between concerns about execution and possible dilution and hopes that Anktivas bladder-cancer expansion, the BCG-nave filing, and the sepsis study will support growth; upcoming investor conferences are a focal point for possible clarity.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs steep pullback is being discussed as a reversal of a rapid rally fueled by hopes that Nvidias leadership turmoil would send AI-chip business AMDs way. Traders disagree over whether the drop is routine profit-taking after an overextended run or a broader reassessment of AI-sector valuations and spending, with Nvidias upcoming results seen as an important test.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco shares are selling off despite a strong quarterly beat and raised full-year outlook, as traders focus on lower gross margins, slower product-order growth and a sequentially lower revenue outlook. The community is split between calling the reaction an overdone dip and worrying that AI-related hardware mix and growth expectations may weigh on profitability.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel pushed its planned BLA filing for its lead prostate cancer therapy to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff. Traders are divided over whether this is a manageable manufacturing and testing delay with the clinical data intact or a sign of management and execution problems, with some also concerned about potential dilution and the CEOs share sales.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Virs discounted public share offering has triggered a sharp selloff amid concerns about dilution. Traders disagree over whether the cash will support upcoming trials and strengthen the companys position in future deals, or whether the raise was unnecessary given its existing cash reserves and undermines confidence in management.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arms earnings beat has been overshadowed by slower royalty growth and a Q3 outlook seen as offering limited upside, adding pressure amid a broader selloff in AI and semiconductor stocks. Traders are split between concerns about Arms high valuation and dependence on chip shipments, and optimism about data-center demand and its expanding AI CPU business.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is rallying after quarterly results showed strong revenue and profit growth alongside improved operating efficiency, with its new full-service bank status in Mexico adding to the growth narrative. Traders are debating whether those results outweigh rising delinquencies and credit costs, which could pressure future profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Next Quantum Breakthrough May Depend on Integration, Not Just Processing Power $QBTQ.CN $QBTQF https://ibn.fm/CYodw

Disseminated on behalf of SuperQ Quantum Computing Inc. and may include paid advertisements. Quantum computing is often discussed in terms of processor performance, qubit counts and the potential to solve increasingly complex problems. Yet, as the technology advances, another consideration is becoming increasingly important: how effectively quantum processors can work alongside the classical computing systems ...

TechMediaWire

The Next Quantum Breakthrough May Depend on Integration, Not Just Processing Power - TechMediaWire

StockTwits Web

SuperQ Quantum Computing Inc.

The Next Quantum Breakthrough May Depend on Integration, Not Just Processing Power $QBTQ.CN 